Market Trends of Amblyopia Treatment Industry
The Strabismic Amblyopia Segment is Expected to Hold a Significant Market Share in the Amblyopia Treatment Market
Strabismus, a condition where the eyes do not align properly, is a risk factor for the development of amblyopia. In this condition, the brain tends to ignore the image from the misaligned eye to avoid double vision, which can further inhibit the visual development of the affected eye.
According to an article published in Investigative Ophthalmology and Visual Science in June 2022, strabismus and amblyopia occur in approximately 3% of children by age three in the United States. Similarly, according to an article published in Taylor and Francis Online in December 2022, the overall prevalence of strabismus in Africa was estimated to be 0.8%.
Moreover, according to an article published in Medicina in January 2024, in children younger than three, 80% of cases of amblyopia were majorly due to strabismus. Hence, the prevalence of strabismus in various parts of the world is expected to drive the segment revenue over the forecast period.
Furthermore, the increasing research and development activities regarding strabismus are also expected to drive market growth. For instance, according to a clinical trial conducted at Boston Children's Hospital in September 2023, a small open-label clinical trial of donepezil raised hope for restoring some lost vision in older children and even adults with amblyopia that developed due to strabismus.
Thus, the rising prevalence of strabismus and increasing research activities are expected to drive the segment revenue over the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America holds a significant share of the market studied due to the high number of people suffering from amblyopia, the developed healthcare industry in the region, and the presence of advanced treatment options and rising product launches. The rising prevalence of amblyopia in North America is expected to drive the market studied over the forecast period. For instance, according to an article published in Frontiers in Pediatrics in May 2022, the prevalence rate of amblyopia in the United States was 2.41% in 2022. Similarly, according to an article published in JAMA Network in January 2024, around 3-5% of young children in schools in Canada were diagnosed with amblyopia. Hence, the high prevalence of amblyopia across North America is expected to drive the market studied over the forecast period.
Furthermore, the increasing investments in research and development of eye-related diseases are also expected to drive market growth. For instance, as per the updated data from the Centers for Disease Control and Prevention in May 2024, around USD 1,146 million was invested in eye diseases in 2023 compared to USD 1,097 million in 2022.
Hence, the increasing investments in eye diseases are expected to drive new product launches for the treatment of amblyopia, which may ultimately drive the growth of the market studied over the forecast period.
